AstraZeneca has ridden a strong oncology and specialty medicines story into a complex valuation debate, and the real question ...

AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in AZN shares today? Let’s find out!

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...

In the latest trading session, Astrazeneca (AZN) closed at $166.68, marking a +2.87% move from the previous day. This move outpaced the S&P 500's daily gain of 0.33%. Elsewhere, the Dow saw an upswing ...

AstraZeneca (ISIN GB0009895292) secured European Union approval for Enhertu in adjuvant treatment of adults with residual ...

The London quotation stood at GBp 12,440 at 3:28 p.m. London time on October 19, 2026.

Market CapN/A Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary. We spent over half ...

AstraZeneca Plc(NYSE: AZN) reported updated clinical outcomes across its oncology portfolio, demonstrating sustained long-term survival advantages in lung cancer treatments alongside mixed findings in ...

AstraZeneca remains a long-term Buy despite recent setbacks, underpinned by robust product and pipeline strength. Click here ...

AstraZeneca (AZN) stock came under pressure on Sept. 29 after the pharma giant announced a massive $2 billion investment in Summit Therapeutics (SMMT). As investors responded to the disclosure, AZN ...